Table 3.

The relationship between BOLA family members and PFS in other different subtypes of OC (Kaplan-Meier plotter)

Subtypes		BOLA1			BOLA2			BOLA3
		Cases	HR (95% CI)	P value	Cases	HR (95% CI)	P value	Cases	HR (95% CI)	Pvalue
Histology	Serous	483	0.93(0.81–1.08)	0.33	483	0.8(0.69–0.93)	0.0048	483	1.36(1.08–1.72)	0.0091
	Endometrioid	44	2.19(0.84–5.7)	0.10	44	2.05(0.81–5.21)	0.12	44	1.95(0.44–8.72)	0.37
Stage	1	96	1.72 (0.59–5.01)	0.32	96	0.27 (0.1–0.79)	0.01	74	0.62 (0.17–2.2)	0.46
	2	67	1.6 (0.69–3.73)	0.27	67	0.29 (0.12–0.72)	0.0047	41	1.94 (0.56–6.73)	0.29
	3	919	0.82 (0.71–0.96)	0.013	919	0.81(0.7–0.95)	0.0083	424	1.21 (0.95–1.53)	0.13
	4	162	1.52 (1.04–2.24)	0.031	162	0.59 (0.38–0.92)	0.018	70	0.60 (0.34–1.07)	0.082
Grade	1 + 2	293	1.48 (1.04–2.1)	0.028	293	0.69 (0.52–0.92)	0.0098	189	1.66 (1.13–2.44)	0.0085
	3	837	1.11 (0.92–1.34)	0.3	837	0.85 (0.72–1)	0.049	315	0.74 (0.55–0.99)	0.04
TP53	Mutated	483	1.24 (0.99–1.56)	0.065	483	0.7 (0.56–0.88)	0.0018	124	1.30 (0.87–1.94)	0.19
	WT	84	0.62 (0.36–1.06)	0.077	84	0.54 (0.31–0.95)	0.031	19	0.60(0.21–1.73)	0.34
CR	Platin	1259	0.85 (0.75–0.97)	0.018	1259	0.79 (0.69–0.91)	< 0.001	502	0.81 (0.65–1)	0.054
	Taxol	715	0.87 (0.74–1.04)	0.12	715	0.8 (0.67–0.95)	0.011	381	1.30(1–1.69)	0.046
	Taxol + platin	698	0.89 (0.75–1.06)	0.2	698	0.81 (0.68–0.97)	0.021	380	1.301–1.69)	0.049

The bold font indicates the difference was significant statistically

OC ovarian cancer, PFS progression-free survival, WT wild type, CR Chemotherapy Regimen